Cocrystal Pharma to Present at the H.C. Wainwright 22nd Annual Global Investment Conference
September 08 2020 - 8:00AM
Cocrystal Pharma, Inc. (NASDAQ: COCP), (“Cocrystal” or
the “Company”), a clinical stage biotechnology company
discovering and developing novel antiviral therapeutics,
today announced that Dr. Gary Wilcox, Chairman and Chief Executive
Officer of Cocrystal, will present at H.C. Wainwright 22nd Annual
Global Investment Conference on Monday, September 14, 2020 at 3:30
PM EDT.
In addition to the presentation, management will
also be available to participate in virtual one-on-one meetings
with qualified members of the investor community who are registered
to attend the conference. For more information, please visit the
conference website here.
A live video webcast of the presentation will be
available on the IR Calendar page of the Investors section of the
Company’s website (cocrystalpharma.com). The video webcast replay
will be made available two hours following the event.
About Cocrystal Pharma,
Inc.
Cocrystal Pharma, Inc. is a clinical stage
biotechnology company discovering and developing novel antiviral
therapeutics that target the replication process of influenza
viruses, SARS-CoV-2 virus, hepatitis C viruses, and norovirus
infections. Cocrystal employs unique structure-based technologies
and Nobel Prize winning expertise to create first- and
best-in-class antiviral drugs. For further information about
Cocrystal, please visit www.cocrystalpharma.com.
Investor and Media Contact:
JTC Team, LLC(833) 475-8247COCP@jtcir.com
###
Cocrystal Pharma (NASDAQ:COCP)
Historical Stock Chart
From Mar 2024 to Apr 2024
Cocrystal Pharma (NASDAQ:COCP)
Historical Stock Chart
From Apr 2023 to Apr 2024